Dr. John Hey serves as the Chief Scientific Officer at Alzheon, Inc. He has held senior leadership positions in drug development at several biotechnology companies including CoMentis and NormOxys, focusing on Alzheimer’s disease and oncology, respectively. As Senior Vice President of Discovery and Preclinical Drug Development at CoMentis, Dr. Hey served as the senior leader and drug development officer responsible for the beta-secretase inhibitor drug development program for Alzheimer’s disease. Prior to his tenure at CoMentis, Dr. Hey spent 18 years at the Schering-Plough Research Institute leading discovery, preclinical, and early clinical development teams in multiple therapeutic areas through Phase 2 development. During this time, he was also a divisional leader, managing preclinical discovery, lead optimization, early development activities, and strategic planning for over 50 scientists. Dr. Hey has developed new chemical entities (NCEs) in multiple therapeutic areas and has been directly responsible for the discovery and development of over 20 NCEs, including several that have advanced to the NDA stage and approval. Dr. Hey supported Phase 3 and Phase 4 programs for Schering-Plough’s respiratory disease franchise portfolio, including Claritin®/Clarinex®, Asmanex®, and Nasonex®. Dr. Hey holds a Ph.D. in Pharmacology from the University of Oklahoma Health Sciences Center and has authored more than 145 peer-reviewed scientific publications.
Dr. John Hey serves as the Chief Scientific Officer at Alzheon, Inc. He has held senior leadership positions in drug development at several biotechnology companies including CoMentis and NormOxys, focusing on Alzheimer’s disease and oncology, respectively. As Senior Vice President of Discovery and Preclinical Drug Development at CoMentis, Dr. Hey served as the senior leader and drug development officer responsible for the beta-secretase inhibitor drug development program for Alzheimer’s disease. Prior to his tenure at CoMentis, Dr. Hey spent 18 years at the Schering-Plough Research Institute leading discovery, preclinical, and early clinical development teams in multiple therapeutic areas through Phase 2 development. During this time, he was also a divisional leader, managing preclinical discovery, lead optimization, early development activities, and strategic planning for over 50 scientists. Dr. Hey has developed new chemical entities (NCEs) in multiple therapeutic areas and has been directly responsible for the discovery and development of over 20 NCEs, including several that have advanced to the NDA stage and approval. Dr. Hey supported Phase 3 and Phase 4 programs for Schering-Plough’s respiratory disease franchise portfolio, including Claritin®/Clarinex®, Asmanex®, and Nasonex®. Dr. Hey holds a Ph.D. in Pharmacology from the University of Oklahoma Health Sciences Center and has authored more than 145 peer-reviewed scientific publications.